<DOC>
	<DOCNO>NCT02527746</DOCNO>
	<brief_summary>A Phase I , dose escalation study evaluation safety pharmacokinetics/pharmacodynamics F-627 female breast cancer patient receive 4 cycle Epirubicin Cyclophosphamide . 18 patient ( 6 patient cohort ) assign three escalate dose cohort 80 , 240 320 µg/kg .</brief_summary>
	<brief_title>Study F-627 Women With Breast Cancer Receiving Myelotoxic Chemotherapy</brief_title>
	<detailed_description>A Phase I , dose escalation study evaluation safety pharmacokinetics/pharmacodynamics F-627 female breast cancer patient receive 4 cycle EC chemotherapy ( Epirubicin plus Cyclophosphamide ) . 18 patient ( 6 patient cohort ) assign three sequential dos cohort F-627 dose 80 , 240 320 µg/kg . The patient receive chemotherapy ( 100 mg/m2 epirubicin 600 mg/m2 cyclophosphamide ) administrate i.v . injection Day 1 F-627 s.c. injection Day 3 cycle 4 cycle . If dose-limiting toxicity ( DLT ) observe 6 patient first cycle , next cohort escalate . Blood sample collect complete blood count differential , serum F-627 concentration safety evaluation different point follow F-672 injection . The decision proceed next high dose make jointly sponsor 's medical expert investigator base upon review safety data first cycle treatment .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Neutropenia</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Epirubicin</mesh_term>
	<mesh_term>Lenograstim</mesh_term>
	<criteria>1 . 1875 year old . 2 . Female breast cancer patient resection plan receive 4 cycle adjuvant chemotherapy contain epirubicin cyclophosphamide . 3 . East Cooperative Oncology Group ( ECOG ) performance 01 . 4 . Absolute neutrophil count ( ANC ) ≥ 2.0 × 109/L , hemoglobin ( Hb ) ≥ 11.0 g/dl , platelet ( PLT ) ≥ 100 × 109/L prior chemotherapy . 5 . Liver kidney function test within normal reference range . 6 . Left ventricular ejection fraction ( LVEF ) &gt; 50 % . 7 . Willing provide write informed consent compliant study procedure . 1 . Pregnancy lactate woman ; female pregnancy potential positive pregnancy test prior study treatment . 2 . Expected survival &lt; 12 month . 3 . Patients receive radiotherapy within 4 week prior enrollment . 4 . Patients receive neoadjuvant chemotherapy prior resection breast cancer . 5 . Patients receive bone marrow hemopoietic stem cell transplantation ; 6 . Patient metastatic cancer breast cancer . 7 . Patients receive Granulocyte Colonystimulating Factor ( GCSF ) treatment within 6 week prior enrollment . 8 . Acute congestive heart failure , myocardial disease , myocardial infarction diagnose clinical , electrocardiography , medical procedure . 9 . Any disease possibly cause splenomegaly . 10 . Acute infection , chronic active hepatitis B infection within 1 year ( except subject negative hepatitis B antigen prior enrollment ) history hepatitis C infection . 11 . Patients active tuberculosis ( TB ) , ever history close contact patient TB except negative result tuberculin test ; TB treatment ; suspect TB chest Xray . 12 . Known positive result human immunodeficiency virus ( HIV ) patient acquire immune deficiency syndrome ( AIDS ) . 13 . Patients sicklecell anemia . 14 . Patients alcohol abuse drug addiction may affect compliance study . 15 . Patients allergy protein extract Escherichia coli , GCSF , drug excipient . 16 . Patients take investigational product within 4 week prior enrollment . 17 . Patients diseases symptom may suitable enrol study base investigator 's judgment .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>August 2015</verification_date>
</DOC>